CAR-T cell therapy for grade 4 brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new treatment called TH-CAR-027 for people with grade 4 gliomas (a type of aggressive brain tumor) that have come back or grown after standard therapy. The treatment uses your own immune cells, which are modified in a lab to target a protein called B7-H3 on tumor cells, and then given back to you. The goal is to see if this therapy can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a grade 4 glioma (like glioblastoma) that has returned or worsened after standard treatment, and you cannot or choose not to have more surgery.
- Your tumor must have at least 30% of cells showing a protein called B7-H3.
- You are between 18 and 75 years old.
- You are able to walk and care for yourself most of the time (KPS score at least 60 or ECOG 0-1).
- Your heart, lungs, blood counts, liver, and kidneys are working well enough based on standard tests.
- You have not had a CAR-T cell therapy or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Hear when a new R/R Grade 4 Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.